P2 receptor excitation of rodent hypoglossal motoneuron activity in vitro and in vivo: a molecular physiological analysis.
The role of P2 receptors in controlling hypoglossal motoneuron (XII MN) output was examined (1) electrophysiologically, via application of ATP to the hypoglossal nucleus of rhythmically active mouse medullary slices and anesthetized adult rats; (2) immunohistochemically, using an antiserum against the P2X2 receptor subunit; and (3) using PCR to identify expression of P2X2 receptor subunits in micropunches of tissue taken from the XII motor nucleus. Application of ATP to the hypoglossal nucleus of mouse medullary slices and anesthetized rats produced a suramin-sensitive excitation of hypoglossal nerve activity. Additional in vitro effects included potentiation of inspiratory hypoglossal nerve output via a suramin- and pyridoxal-phosphate-6-azophenyl-2',4'-disulphonic acid (PPADS)-sensitive mechanism, XII MN depolarization via activation of a suramin-sensitive inward current, decreased neuronal input resistance, and a slow-onset theophylline-sensitive reduction of inspiratory output likely resulting from hydrolysis of extracellular ATP to adenosine and activation of P1 receptors. Immunohistochemically, P2X2 receptors were detected in inspiratory XII MNs that were labeled with Lucifer yellow. These data, combined with identification of mRNA for three P2X2 receptor subunit isoforms within the hypoglossal nucleus (two of which have not been localized previously in brain) and the previous demonstration that P2X receptors are ubiquitously expressed in cranial and spinal motoneuron pools, support not only a role of P2 receptors in modulating inspiratory hypoglossal activity but a general role of P2 receptors in modulating motor outflow from the CNS.
Funk
G D
GD
Department of Physiology, Faculty of Medicine and Health Science, University of Auckland, Auckland, New Zealand.
Kanjhan
R
R
Walsh
C
C
Lipski
J
J
Comer
A M
AM
Parkis
M A
MA
Housley
G D
GD
D000241:Adenosine / Q000494:pharmacology; D000255:Adenosine Triphosphate / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D000970:Antineoplastic Agents / Q000494:pharmacology; D004594:Electrophysiology; D015870:Gene Expression / Q000502:physiology; D007002:Hypoglossal Nerve / Q000737:chemistry / Q000166:cytology* / Q000502:physiology; D007150:Immunohistochemistry; D066298:In Vitro Techniques; D008526:Medulla Oblongata / Q000737:chemistry / Q000166:cytology / Q000502:physiology; D051379:Mice; D009046:Motor Neurons / Q000737:chemistry* / Q000187:drug effects / Q000502:physiology; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D016133:Polymerase Chain Reaction; D011732:Pyridoxal Phosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D018048:Receptors, Purinergic P2 / Q000032:analysis / Q000235:genetics / Q000378:metabolism*; D058486:Receptors, Purinergic P2X7; D012119:Respiration / Q000502:physiology; D013498:Suramin / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology
D000970:Antineoplastic Agents; C546469:P2rx7 protein, mouse; D010975:Platelet Aggregation Inhibitors; D018048:Receptors, Purinergic P2; D058486:Receptors, Purinergic P2X7; D014665:Vasodilator Agents; C077792:pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid; D011732:Pyridoxal Phosphate; D013498:Suramin; D000255:Adenosine Triphosphate; D000241:Adenosine